{
  "DOI": "10.1186/1479-7364-3-1-7",
  "ISSN": [
    "1479-7364"
  ],
  "URL": "http://dx.doi.org/10.1186/1479-7364-3-1-7",
  "alternative-id": [
    "215"
  ],
  "article-number": "7",
  "author": [
    {
      "affiliation": [],
      "family": "Aquilante",
      "given": "Christina L",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Bushman",
      "given": "Lane R.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Knutsen",
      "given": "Shannon D.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Burt",
      "given": "Lauren E.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Rome",
      "given": "Lucille Capo",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Kosmiski",
      "given": "Lisa A.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genomics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": []
  },
  "created": {
    "date-parts": [
      [
        2019,
        12,
        10
      ]
    ],
    "date-time": "2019-12-10T21:29:44Z",
    "timestamp": 1576013384000
  },
  "deposited": {
    "date-parts": [
      [
        2019,
        12,
        10
      ]
    ],
    "date-time": "2019-12-10T21:29:47Z",
    "timestamp": 1576013387000
  },
  "indexed": {
    "date-parts": [
      [
        2023,
        11,
        19
      ]
    ],
    "date-time": "2023-11-19T00:55:44Z",
    "timestamp": 1700355344291
  },
  "is-referenced-by-count": 44,
  "issn-type": [
    {
      "type": "electronic",
      "value": "1479-7364"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2008,
        9,
        1
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-print": {
      "date-parts": [
        [
          2008,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "http://www.springer.com/tdm",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2008,
            9,
            1
          ]
        ],
        "date-time": "2008-09-01T00:00:00Z",
        "timestamp": 1220227200000
      }
    }
  ],
  "link": [
    {
      "URL": "http://link.springer.com/content/pdf/10.1186/1479-7364-3-1-7.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/article/10.1186/1479-7364-3-1-7/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/content/pdf/10.1186/1479-7364-3-1-7.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1186",
  "published": {
    "date-parts": [
      [
        2008,
        9,
        1
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2008,
        9,
        1
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2008,
        12
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1056/NEJMra041001",
      "author": "H Yki-Jarvinen",
      "doi-asserted-by": "publisher",
      "first-page": "1106",
      "journal-title": "N Engl J Med",
      "key": "215_CR1",
      "unstructured": "Yki-Jarvinen H: Thiazolidinediones. N Engl J Med. 2004, 351: 1106-1118. 10.1056/NEJMra041001.",
      "volume": "351",
      "year": "2004"
    },
    {
      "key": "215_CR2",
      "unstructured": "Actos Prescribing Information. 2007, Takeda Pharmaceuticals America, Inc."
    },
    {
      "key": "215_CR3",
      "unstructured": "Avandia Prescribing Information. 2007, GlaxoSmithKline"
    },
    {
      "DOI": "10.1111/j.1365-2125.2007.02986.x",
      "author": "A Kalliokoski",
      "doi-asserted-by": "publisher",
      "first-page": "78",
      "journal-title": "Br J Clin Pharmacol",
      "key": "215_CR4",
      "unstructured": "Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M: No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br J Clin Pharmacol. 2008, 65: 78-86. 10.1111/j.1365-2125.2007.02986.x.",
      "volume": "65",
      "year": "2008"
    },
    {
      "DOI": "10.2337/diacare.26.3.825",
      "author": "M Bluher",
      "doi-asserted-by": "publisher",
      "first-page": "825",
      "journal-title": "Diabetes Care",
      "key": "215_CR5",
      "unstructured": "Bluher M, Lubben G, Paschke R: Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care. 2003, 26: 825-831. 10.2337/diacare.26.3.825.",
      "volume": "26",
      "year": "2003"
    },
    {
      "DOI": "10.2337/diacare.27.6.1365",
      "author": "S Snitker",
      "doi-asserted-by": "publisher",
      "first-page": "1365",
      "journal-title": "Diabetes Care",
      "key": "215_CR6",
      "unstructured": "Snitker S, Watanabe RM, Ani I, et al: Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: Results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care. 2004, 27: 1365-1368. 10.2337/diacare.27.6.1365.",
      "volume": "27",
      "year": "2004"
    },
    {
      "DOI": "10.1016/j.clpt.2005.04.013",
      "author": "ES Kang",
      "doi-asserted-by": "publisher",
      "first-page": "202",
      "journal-title": "Clin Pharmacol Ther",
      "key": "215_CR7",
      "unstructured": "Kang ES, Park SY, Kim HJ, et al: Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther. 2005, 78: 202-208. 10.1016/j.clpt.2005.04.013.",
      "volume": "78",
      "year": "2005"
    },
    {
      "DOI": "10.2337/diacare.28.5.1139",
      "author": "ES Kang",
      "doi-asserted-by": "publisher",
      "first-page": "1139",
      "journal-title": "Diabetes Care",
      "key": "215_CR8",
      "unstructured": "Kang ES, Park SY, Kim HJ, et al: The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care. 2005, 28: 1139-1144. 10.2337/diacare.28.5.1139.",
      "volume": "28",
      "year": "2005"
    },
    {
      "DOI": "10.2337/dc05-2466",
      "author": "ES Kang",
      "doi-asserted-by": "publisher",
      "first-page": "1320",
      "journal-title": "Diabetes Care",
      "key": "215_CR9",
      "unstructured": "Kang ES, Cha BS, Kim HJ, et al: The 11482G \u003e A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes. Diabetes Care. 2006, 29: 1320-1324. 10.2337/dc05-2466.",
      "volume": "29",
      "year": "2006"
    },
    {
      "DOI": "10.1210/jc.2006-2275",
      "author": "JC Florez",
      "doi-asserted-by": "publisher",
      "first-page": "1502",
      "journal-title": "J Clin Endocrinol Metab",
      "key": "215_CR10",
      "unstructured": "Florez JC, Jablonski KA, Sun MW, et al: Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab. 2007, 92: 1502-1509. 10.1210/jc.2006-2275.",
      "volume": "92",
      "year": "2007"
    },
    {
      "DOI": "10.2337/diabetes.54.11.3319",
      "author": "JK Wolford",
      "doi-asserted-by": "publisher",
      "first-page": "3319",
      "journal-title": "Diabetes",
      "key": "215_CR11",
      "unstructured": "Wolford JK, Yeatts KA, Dhanjal SK, et al: Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes. 2005, 54: 3319-3325. 10.2337/diabetes.54.11.3319.",
      "volume": "54",
      "year": "2005"
    },
    {
      "DOI": "10.1111/j.1742-1241.2006.01242.x",
      "author": "G Wang",
      "doi-asserted-by": "publisher",
      "first-page": "552",
      "journal-title": "Int J Clin Pract",
      "key": "215_CR12",
      "unstructured": "Wang G, Wang X, Zhang Q, Ma Z: Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus. Int J Clin Pract. 2007, 61: 552-557. 10.1111/j.1742-1241.2006.01242.x.",
      "volume": "61",
      "year": "2007"
    },
    {
      "DOI": "10.1210/jc.2006-0590",
      "author": "L Hansen",
      "doi-asserted-by": "publisher",
      "first-page": "3446",
      "journal-title": "J Clin Endocrinol Metab",
      "key": "215_CR13",
      "unstructured": "Hansen L, Ekstrom CT, Tabanera YPR, et al: The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab. 2006, 91: 3446-3450. 10.1210/jc.2006-0590.",
      "volume": "91",
      "year": "2006"
    },
    {
      "DOI": "10.1046/j.1365-2125.1999.00030.x",
      "author": "SJ Baldwin",
      "doi-asserted-by": "publisher",
      "first-page": "424",
      "journal-title": "Br J Clin Pharmacol",
      "key": "215_CR14",
      "unstructured": "Baldwin SJ, Clarke SE, Chenery RJ: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 1999, 48: 424-432.",
      "volume": "48",
      "year": "1999"
    },
    {
      "DOI": "10.1016/S0006-2952(02)01354-0",
      "author": "N Bahadur",
      "doi-asserted-by": "publisher",
      "first-page": "1579",
      "journal-title": "Biochem Pharmacol",
      "key": "215_CR15",
      "unstructured": "Bahadur N, Leathart JB, Mutch E, et al: CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol. 2002, 64: 1579-1589. 10.1016/S0006-2952(02)01354-0.",
      "volume": "64",
      "year": "2002"
    },
    {
      "DOI": "10.1097/00008571-200110000-00006",
      "author": "D Dai",
      "doi-asserted-by": "publisher",
      "first-page": "597",
      "journal-title": "Pharmacogenetics",
      "key": "215_CR16",
      "unstructured": "Dai D, Zeldin DC, Blaisdell JA, et al: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001, 11: 597-607. 10.1097/00008571-200110000-00006.",
      "volume": "11",
      "year": "2001"
    },
    {
      "DOI": "10.1248/bpb.24.1427",
      "author": "A Soyama",
      "doi-asserted-by": "publisher",
      "first-page": "1427",
      "journal-title": "Biol Pharm Bull",
      "key": "215_CR17",
      "unstructured": "Soyama A, Saito Y, Hanioka N, et al: Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull. 2001, 24: 1427-1430. 10.1248/bpb.24.1427.",
      "volume": "24",
      "year": "2001"
    },
    {
      "DOI": "10.1016/j.clpt.2006.09.008",
      "author": "J Kirchheiner",
      "doi-asserted-by": "publisher",
      "first-page": "657",
      "journal-title": "Clin Pharmacol Ther",
      "key": "215_CR18",
      "unstructured": "Kirchheiner J, Thomas S, Bauer S, et al: Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther. 2006, 80: 657-667. 10.1016/j.clpt.2006.09.008.",
      "volume": "80",
      "year": "2006"
    },
    {
      "author": "MW Hruska",
      "first-page": "PI",
      "journal-title": "Clin PharmacolTher",
      "key": "215_CR19",
      "unstructured": "Hruska MW, Cheong JA, Amico JA, et al: Effect of CYP2C8 genotype on rosiglitazone pharmacokinetics. Clin PharmacolTher. 2005, P36: PI-107.",
      "volume": "P36",
      "year": "2005"
    },
    {
      "DOI": "10.1111/j.1365-2125.2006.02706.x",
      "author": "RS Pedersen",
      "doi-asserted-by": "publisher",
      "first-page": "682",
      "journal-title": "Br J Clin Pharmacol",
      "key": "215_CR20",
      "unstructured": "Pedersen RS, Damkier P, Brosen K: The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol. 2006, 62: 682-689. 10.1111/j.1365-2125.2006.02706.x.",
      "volume": "62",
      "year": "2006"
    },
    {
      "DOI": "10.1124/jpet.104.082370",
      "author": "C Chang",
      "doi-asserted-by": "publisher",
      "first-page": "533",
      "journal-title": "J Pharmacol ExpTher",
      "key": "215_CR21",
      "unstructured": "Chang C, Pang KS, Swaan PW, Ekins S: Comparative pharmacophore modeling of organic anion transporting polypeptides: A meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol ExpTher. 2005, 314: 533-541.",
      "volume": "314",
      "year": "2005"
    },
    {
      "DOI": "10.1016/j.clpt.2005.05.011",
      "author": "RH Ho",
      "doi-asserted-by": "publisher",
      "first-page": "260",
      "journal-title": "Clin Pharmacol Ther",
      "key": "215_CR22",
      "unstructured": "Ho RH, Kim RB: Transporters and drug therapy: Implications for drug disposition and disease. Clin Pharmacol Ther. 2005, 78: 260-277. 10.1016/j.clpt.2005.05.011.",
      "volume": "78",
      "year": "2005"
    },
    {
      "DOI": "10.1016/j.ejps.2005.12.003",
      "author": "Y Shitara",
      "doi-asserted-by": "publisher",
      "first-page": "425",
      "journal-title": "Eur J Pharm Sci",
      "key": "215_CR23",
      "unstructured": "Shitara Y, Horie T, Sugiyama Y: Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci. 2006, 27: 425-446. 10.1016/j.ejps.2005.12.003.",
      "volume": "27",
      "year": "2006"
    },
    {
      "DOI": "10.1074/jbc.M103792200",
      "author": "RG Tirona",
      "doi-asserted-by": "publisher",
      "first-page": "35669",
      "journal-title": "J Biol Chem",
      "key": "215_CR24",
      "unstructured": "Tirona RG, Leake BF, Merino G, Kim RB: Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 2001, 276: 35669-35675. 10.1074/jbc.M103792200.",
      "volume": "276",
      "year": "2001"
    },
    {
      "DOI": "10.1007/s00210-006-0040-y",
      "author": "J Konig",
      "doi-asserted-by": "publisher",
      "first-page": "432",
      "journal-title": "Naunyn Schmiedebergs Arch Pharmacol",
      "key": "215_CR25",
      "unstructured": "Konig J, Seithel A, Gradhand U, Fromm MF: Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 2006, 372: 432-443. 10.1007/s00210-006-0040-y.",
      "volume": "372",
      "year": "2006"
    },
    {
      "DOI": "10.1097/01.fpc.0000170913.73780.5f",
      "author": "Y Kameyama",
      "doi-asserted-by": "publisher",
      "first-page": "513",
      "journal-title": "Pharmacogenet Genomics",
      "key": "215_CR26",
      "unstructured": "Kameyama Y, Yamashita K, Kobayashi K, et al: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005, 15: 513-522. 10.1097/01.fpc.0000170913.73780.5f.",
      "volume": "15",
      "year": "2005"
    },
    {
      "DOI": "10.1007/s11095-006-9159-2",
      "author": "KT Kivisto",
      "doi-asserted-by": "publisher",
      "first-page": "239",
      "journal-title": "Pharm Res",
      "key": "215_CR27",
      "unstructured": "Kivisto KT, Niemi M: Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res. 2007, 24: 239-247. 10.1007/s11095-006-9159-2.",
      "volume": "24",
      "year": "2007"
    },
    {
      "DOI": "10.1177/0091270007311569",
      "author": "A Kalliokoski",
      "doi-asserted-by": "publisher",
      "first-page": "311",
      "journal-title": "J Clin Pharmacol",
      "key": "215_CR28",
      "unstructured": "Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M: Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol. 2008, 48: 311-321. 10.1177/0091270007311569.",
      "volume": "48",
      "year": "2008"
    },
    {
      "DOI": "10.1097/01.fpc.0000114750.08559.32",
      "author": "M Niemi",
      "doi-asserted-by": "publisher",
      "first-page": "429",
      "journal-title": "Pharmacogenetics",
      "key": "215_CR29",
      "unstructured": "Niemi M, Schaeffeler E, Lang T, et al: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-CSLCO1B1). Pharmacogenetics. 2004, 14: 429-440. 10.1097/01.fpc.0000114750.08559.32.",
      "volume": "14",
      "year": "2004"
    },
    {
      "DOI": "10.1016/j.clpt.2005.01.018",
      "author": "M Niemi",
      "doi-asserted-by": "publisher",
      "first-page": "468",
      "journal-title": "Clin Pharmacol Ther",
      "key": "215_CR30",
      "unstructured": "Niemi M, Backman JT, Kajosaari LI, et al: Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005, 77: 468-478. 10.1016/j.clpt.2005.01.018.",
      "volume": "77",
      "year": "2005"
    },
    {
      "DOI": "10.1592/phco.22.12.954.33598",
      "author": "TE Andrisin",
      "doi-asserted-by": "publisher",
      "first-page": "954",
      "journal-title": "Pharmacotherapy",
      "key": "215_CR31",
      "unstructured": "Andrisin TE, Humma LM, Johnson JA: Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy. 2002, 22: 954-960. 10.1592/phco.22.12.954.33598.",
      "volume": "22",
      "year": "2002"
    },
    {
      "DOI": "10.1016/j.jchromb.2004.01.010",
      "author": "MW Hruska",
      "doi-asserted-by": "publisher",
      "first-page": "317",
      "journal-title": "J Chromatogr B Analyt Technol Biomed Life Sci",
      "key": "215_CR32",
      "unstructured": "Hruska MW, Frye RF: Simplified method for determination of rosiglitazone in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004, 803: 317-320. 10.1016/j.jchromb.2004.01.010.",
      "volume": "803",
      "year": "2004"
    },
    {
      "DOI": "10.1124/dmd.107.018010",
      "author": "A Tornio",
      "doi-asserted-by": "publisher",
      "first-page": "73",
      "journal-title": "Drug Metab Dispos",
      "key": "215_CR33",
      "unstructured": "Tornio A, Niemi M, Neuvonen PJ, Backman JT: Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos. 2008, 36: 73-80.",
      "volume": "36",
      "year": "2008"
    },
    {
      "DOI": "10.1007/s00125-003-1181-x",
      "author": "M Niemi",
      "doi-asserted-by": "publisher",
      "first-page": "1319",
      "journal-title": "Diabetologia",
      "key": "215_CR34",
      "unstructured": "Niemi M, Backman JT, Granfors M, et al: Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia. 2003, 46: 1319-1323. 10.1007/s00125-003-1181-x.",
      "volume": "46",
      "year": "2003"
    },
    {
      "DOI": "10.1038/sj.tpj.6500482",
      "author": "C Rodriguez-Antona",
      "doi-asserted-by": "publisher",
      "first-page": "268",
      "journal-title": "Pharmacogenomics J",
      "key": "215_CR35",
      "unstructured": "Rodriguez-Antona C, Niemi M, Backman JT, et al: Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. 2007, 8: 268-277.",
      "volume": "8",
      "year": "2007"
    }
  ],
  "reference-count": 35,
  "references-count": 35,
  "resource": {
    "primary": {
      "URL": "https://humgenomics.biomedcentral.com/articles/10.1186/1479-7364-3-1-7"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genomics"
  ],
  "source": "Crossref",
  "title": [
    "Influence of SLCO1B1 and CYP2C8gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers"
  ],
  "type": "journal-article",
  "volume": "3"
}